Unknown PHASE3 INTERVENTIONAL 2-arm NCT01657955

Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients

Sponsor: Shandong Lanjin Pharmaceuticals Co.,Ltd

Conditions Chronic Lymphocytic Leukemia Leukemia Neoplasms

Interventions Bendamustine Hydrochloride Injection Chlorambucil

Updated 5 times since 2017 Last updated: Aug 3, 2012 Started: Jan 31, 2011 Primary completion: Oct 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01657955, this PHASE3 trial focuses on Chronic Lymphocytic Leukemia and Leukemia and remains ongoing. Sponsored by Shandong Lanjin Pharmaceuticals Co.,Ltd, it has been updated 5 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong Lanjin Pharmaceuticals Co.,Ltd

Data source: Shandong Lanjin Pharmaceuticals Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China